Medical Device Registrations in the Middle East
- Marie Dorat
- 2 days ago
- 6 min read
Prepared for: Industry Professionals and Market Entrants |
Author: Marie E. Dorat
Executive Summary
The Middle East medical device market, particularly in the GCC countries, presents substantial opportunities for Class I and Class II devices. This comprehensive guide covers regulatory requirements, documentation strategies, and practical pathways for efficient market entry.
The Middle East offers strong growth for Class I and Class II medical devices. Focus on risk-based registration, ISO 13485, and international approvals (CE/FDA). Harmonization via GCC is advancing.
1. Regulatory Landscape Overview
Medical devices are regulated on a risk-based classification system aligned with IMDRF/GHTF principles.
· Class I: Low risk (e.g., elastic bandages, manual surgical instruments, non-sterile dressings).
· Class II: Moderate risk (e.g., blood pressure monitors, powered wheelchairs, diagnostic ultrasound devices, infusion pumps - non-implantable
· Class III / High-Risk (Class C/D in SFDA; Class III/IV in UAE): High risk – invasive, implantable, life-sustaining (e.g., pacemakers, coronary stents, heart valves, powered implants, advanced drug-eluting devices).
Note on Classification: SFDA uses A–D (A=lowest, D=highest). UAE/Egypt align closely with EU MDR (I–III or I–IV).
Key Regulatory Authorities
Country | Authority |
Saudi Arabia | SFDA (Saudi Food and Drug Authority) |
United Arab Emirates | MOHAP (Ministry of Health and Prevention) |
Egypt | EDA (Egyptian Drug Authority) |
Other GCC | National Ministries of Health / NHRA |
2. Product Dossiers and Regulatory Documentation
A well-structured Summary Technical Documentation (STED) is recommended.
· Device description and specifications (including GMDN code)
· Risk management file (ISO 14971)
· Clinical evaluation report
· Technical and performance testing
· ISO 13485:2016 QMS certificate
· Labeling and IFU (Arabic required in most markets)
· Reference approvals (CE Mark, FDA 510(k), etc.)
Class I Device Example: Disposable Surgical Masks
Low-risk, non-sterile.
Requirement | Details for Surgical Masks | Documentation Needed |
Classification | Class I (non-sterile) | Classification rationale |
Intended Use | Single-use protection against droplets | IFU with Arabic translation |
Risk Management | Low risk - basic ISO 14971 | Simplified risk file |
Technical File | Material specs (non-woven fabric), performance | Biocompatibility (ISO 10993), breathability test |
QMS | ISO 13485 certificate | Valid certificate |
Reference Approvals | CE Mark, FDA 510(k) if applicable | Certificates + Free Sale Certificate |
Labeling | Manufacturer details, lot number, expiry | English + Arabic |
Timeline (SFDA MDNR) | 1-4 weeks | Listing application |
UAE Listing | 2-4 weeks | Basic dossier |
Class II Device Example: Digital Blood Pressure Monitor
Moderate-risk, non-invasive diagnostic.
Requirement | Details for Digital BP Monitor | Documentation Needed |
Classification | Class IIa / Class B (SFDA) | Detailed classification with justification |
Intended Use | Home/clinical blood pressure measurement | Clinical evaluation report |
Risk Management | ISO 14971 full file (electrical, software risks) | Hazard analysis, risk-benefit |
Performance & Safety | Accuracy per ISO 81060, IEC 60601-1 | Test reports, electrical safety |
Clinical Data | Literature review or clinical study | CER (Clinical Evaluation Report) |
Software | IEC 62304 if applicable | Software validation |
Labeling & IFU | Detailed instructions, symbols | Multilingual (English + Arabic) |
Post-Market Surveillance | Vigilance plan | PMS procedure document |
Timeline (SFDA MDMA) | 3-6 months | Full technical dossier review |
UAE Registration | 2-4 months | Manufacturer registration + device file |
Additional Class II Example: Portable ECG Device
Requirement | Details | Key Documents |
Classification | Class IIa/IIb | Risk class justification |
Essential Requirements | Cardiac monitoring accuracy | Performance test reports |
Biocompatibility | Electrodes contact | ISO 10993 series |
Timeline (Egypt EDA) | 6-9 months | Full registration dossier |
Class III / High-Risk Device Example – Coronary Artery Stent (Implantable)
Requirement | Details for Coronary Stent (Class III / SFDA Class C/D) | Documentation Needed |
Classification | High risk – implantable, long-term invasive | Detailed justification + rule application |
Intended Use | Restenosis prevention in coronary arteries | Comprehensive clinical evaluation (full CER) |
Risk Management | Full ISO 14971 with extensive post-market data | Detailed hazard analysis, FMEA, risk-benefit |
Performance & Safety | Mechanical testing, biocompatibility, degradation | ISO 10993 full suite, fatigue testing, animal studies |
Clinical Data | Clinical investigations / pivotal studies required | Full clinical study reports (not just literature) |
QMS | ISO 13485 + possible SFDA audit | Certificate + audit reports |
Labeling & IFU | Detailed implantation instructions | English + Arabic, symbols per standards |
Post-Market Surveillance | Intensive PMS + periodic safety update reports | Detailed PMS plan, vigilance procedures |
Timeline (SFDA MDMA) | 6–12+ months (longer with queries) | Full technical dossier + possible site audit |
UAE (EDE) Timeline | 8–12+ months | Extensive technical committee review |
Egypt (EDA) Timeline | 9–18 months | Full file + possible expert committee |
Additional Notes for Class III: Higher scrutiny on design validation, long-term safety, and real-world evidence.
3. Interfacing with Authorities and Local Partners
Appointment of a Local Authorized Representative (AR) is mandatory in most countries.
AR Responsibilities:
Submit applications via portals (e.g., SFDA GHAD, MOHAP e-services).
Handle communications, queries, and post-market surveillance.
Ensure labeling/import compliance.
Often a licensed distributor or independent regulatory firm (recommended for flexibility).
Best Practices:
Select ARs with proven track records and SFDA/MOHAP licensing.
Use Power of Attorney (legalized).
Build strong relationships with authorities through pre-submission meetings where available.
Partner with local distributors for commercialization while keeping regulatory AR independent if managing multiple channels.
4. Country-Specific Requirements and Timelines
Saudi Arabia (SFDA) — Largest Market
Class I (non-sterile/non-measuring): MDNR Listing (basic info, QMS, reference approval) ~4 working days to 1 month, valid 3 years.
Class II (B/C equivalents): MDMA via Technical File Assessment — 35 official days (realistically 3–6+ months with queries).
Pathways: Reliance on CE/FDA; local AR required.
Fees: Vary by class; higher for detailed reviews.
UAE (MOHAP)
Class I: Listing route (simplified, 2–4 weeks).
Class II: Full evaluation (technical dossier review).
Manufacturer site registration often first step.
Validity: Up to 5 years.
Arabic labeling/IFU critical
Other GCC (Qatar, Kuwait, etc.)
Often accept UAE/Saudi registrations or follow national rules with GCC harmonization.
Bahrain NHRA, Oman MOH portals for higher classes.
Egypt (EDA)
Full registration via local agent; 4–9+ months.
Fast-track for some devices; valid 10 years.
General Timelines (Class I/II): 1–6 months in GCC with strong dossiers; longer if gaps or audits needed.
Note: Country-specific Checklists available
2026 Government Fees (Approximate)
Saudi Arabia (SFDA)
Class A (Low, ~Class I): SAR 15,000
Class B (~Class II): SAR 19,000
Class C (High, ~Class III): SAR 21,000
Class D (Very High): SAR 23,000
UAE (EDE / MOHAP)
Manufacturer Site Registration: AED 10,100
Device Registration: AED 5,000+ (higher for Class III/IV)
Total first-time high-risk: AED 18,000–25,000+
Egypt (EDA)
Normal track: $139 – $298+ (higher for Class III)
Realistic total with fast-track options: Significantly elevated for high-risk devices.
5. Regulatory Strategy and Documentation Harmonization
Reliance Pathways: Leverage CE/FDA approvals to reduce redundant reviews.
Core vs. Country Dossiers: Maintain a master file; customize per market (e.g., add local risk assessments).
QMS Alignment: ISO 13485 as baseline; prepare for potential SFDA audits.
UDI and Labeling: Implement early for traceability.
Risk-Based Approach: Prioritize high-volume or innovative Class II devices.
Post-Market: Establish vigilance systems aligned with local requirements (e.g., PSURs in Saudi).
Harmonization Benefits: UAE approval can ease entry into other GCC states.
Note: Country-specific Document Legalization Requirements available
6. Efficient Market Entry Roadmap Recommended Strategy Class I & II:
Prioritize UAE as a low-friction gateway and reference market.
Simultaneous or Sequential Saudi filing for volume.
Engage regulatory consultants/AR early for dossier gap analysis.
Plan for Arabic translations, local testing (if required), and import logistics (free zones in UAE/Dubai helpful).
Timeline to Launch: 6–12 months for multi-country entry with preparation.
Commercial Steps: Distributor partnerships, tender readiness (government procurement key), pricing/reimbursement analysis.
Monitor updates: SFDA localization pushes, GCC convergence.
Strategy for Class III
Prioritize strong CE Mark (MDR Annex IX or equivalent) or FDA PMA as reference.
Expect mandatory local clinical data or bridging studies in some cases.
Budget for longer timelines (9–18 months per market) and potential on-site audits (especially SFDA).
Use UAE as a reference market where possible before tackling Saudi Arabi
Follow with Saudi Arabia.
Leverage approvals for Kuwait, Qatar, Oman (smaller but growing markets).
For Class III: Expect 9–18+ months total across multiple countries.
Conclusion and Recommendations
Compliant entry into the Middle East requires proactive dossier preparation, strong local partnerships, and a harmonized yet adaptable strategy. Class I/II devices benefit from reliance pathways, enabling faster launches compared to higher-risk products. Success hinges on quality documentation, authority engagement, and understanding cultural/business nuances.
Class III devices require significantly more investment in clinical evidence and regulatory engagement but open doors to high-value segments in the Middle East. A harmonized master dossier with country addendums remains the most efficient approach. Total market entry for a Class III device: 12–24 months with proper planning.
Manufacturers should consult local experts for the latest guidelines, as regulations evolve rapidly. Early investment in a robust regulatory strategy yields faster ROI in this high-growth region.
If you found this article informative and would like to obtain the associated appendices, templates, or expert assistance with registering your medical device in the Middle East or any other countries, we invite you to book a consultation at: https://www.medoratconsult.com/product-registrations
Or contact me directly: medorat@medoratconsult.com
References: Sourced from official authority guidelines, industry reports (SFDA, MOHAP, GCC), and regulatory consultancies (2025–2026 data).
Comments